期刊
PEDIATRIC NEPHROLOGY
卷 35, 期 11, 页码 2113-2120出版社
SPRINGER
DOI: 10.1007/s00467-020-04622-3
关键词
Children; Pyelonephritis; UTI; Dexamethasone; Clinical trials; DMSA; Kidneys
资金
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK087870]
Background To evaluate the efficacy of adjuvant systemic corticosteroids in reducing kidney scarring. A previous study suggested that use of adjuvant systemic corticosteroids reduces kidney scarring in children radiologically confirmed to have extensive pyelonephritis. Efficacy of corticosteroids for children with febrile urinary tract infection (UTI) has not been studied. Methods Children aged 2 months to 6 years with their first febrile UTI were randomized to corticosteroids or placebo for 3 days (both arms received antimicrobial therapy); kidney scarring was assessed using(99m)Tc-dimercaptosuccinic acid kidney scan 5-24 months after the initial UTI. Results We randomized 546 children of which 385 had a UTI and 254 had outcome kidney scans (instead of the 320 planned). Rates of kidney scarring were 9.8% (12/123) and 16.8% (22/131) in the corticosteroid and placebo groups, respectively (p = 0.16), corresponding to an absolute risk reduction of 5.9% (95% confidence interval: - 2.2, 14.1). Conclusion While children randomized to adjuvant corticosteroids tended to develop fewer kidney scars than children who were randomized to receive placebo, a statistically significant difference was not achieved. However, the study was limited by not reaching its intended sample size.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据